Nursing care and management of adverse events for patients with BRAF(V600E)-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review

Encorafenib is a B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) inhibitor, approved in the EU and USA, in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab, for the treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer (mCRC). In the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fowler, Matthew, Tobback, Helene, Karuri, Alice, Fernández-Ortega, Paz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989561/
https://www.ncbi.nlm.nih.gov/pubmed/36881161
http://dx.doi.org/10.1007/s00520-023-07579-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989561/
https://www.ncbi.nlm.nih.gov/pubmed/36881161
http://dx.doi.org/10.1007/s00520-023-07579-9

Ejemplares similares